TNG908

Phase 1/2Active

0 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Locally Advanced Solid Tumor

Conditions

Locally Advanced Solid Tumor

Trial Timeline

Mar 23, 2022 → Dec 1, 2025

NCT ID

NCT05275478

About TNG908

TNG908 is a phase 1/2 stage product being developed by Tango Therapeutics for Locally Advanced Solid Tumor. The current trial status is active. This product is registered under clinical trial identifier NCT05275478. Target conditions include Locally Advanced Solid Tumor.

What happened to similar drugs?

5 of 20 similar drugs in Locally Advanced Solid Tumor were approved

Approved (5) Terminated (1) Active (14)

✅letrozoleJiangsu Hengrui MedicineApproved

✅FulvestrantAstraZenecaApproved

✅PazopanibNovartisApproved

✅LetrozoleNovartisApproved

✅Trastuzumab emtansineRocheApproved

🔄Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3

🔄Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05275478	Phase 1/2	Active	Mar 23, 2022	Dec 1, 2025	Locally Advanced Solid Tumor

Competing Products

20 competing products in Locally Advanced Solid Tumor

See all competitors

Product	Company	Stage	Hype Score
Necitumumab + Gemcitabine + Carboplatin	Eli Lilly	Phase 2	27
Pemetrexed + Erlotinib + Pemetrexed + Erlotinib	Eli Lilly	Phase 2	35
NBTXR3	Nanobiotix	Phase 1/2	33
Tadalafil + Gemcitabine	Eli Lilly	Phase 1	29
SPYK04	Chugai Pharmaceutical	Phase 1	33
LUNA18 + Cetuximab	Chugai Pharmaceutical	Phase 1	21
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + Gemcitabine	Chugai Pharmaceutical	Phase 3	40
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + Pemetrexed	Daiichi Sankyo	Phase 3	44
T-DXd + Durvalumab + Cisplatin + Carboplatin + Pemetrexed + Volrustomig + Rilvegostomig	Daiichi Sankyo	Phase 1	36
ASP2998 + Pembrolizumab + Enfortumab Vedotin + Carboplatin	Astellas Pharma	Phase 1/2	39
zolbetuximab	Astellas Pharma	Pre-clinical	30
enfortumab vedotin + pembrolizumab	Astellas Pharma	Phase 2	39
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracil	Astellas Pharma	Phase 3	44
enfortumab vedotin (EV)	Astellas Pharma	Pre-clinical	26
zolbetuximab	Astellas Pharma	Pre-clinical	33
zolbetuximab + oxaliplatin + capecitabine + placebo	Astellas Pharma	Phase 3	44
ASP3082	Astellas Pharma	Phase 2	42
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + Placebo	Astellas Pharma	Phase 3	47
ASP1948	Astellas Pharma	Phase 1	29
Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )	Sun Pharmaceutical	Phase 2	31